Scotiabank analyst Sung Ji Nam raised the firm’s price target on Castle Biosciences to $37 from $33 and keeps an Outperform rating on the shares post the Q4 report. The company reported another year of strong execution, including 60% year-over-year revenue growth and positive cash flow from operations, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CSTL:
- Castle Biosciences price target raised to $33 from $31 at Baird
- Castle Biosciences files $300M mixed securities shelf
- Castle Biosciences sees FY24 revenue $235M-$240M, consensus $214.7M
- Castle Biosciences reports Q4 EPS (10c), consensus (54c)
- Castle Biosciences Shapes Dialogue with Strategic Presentations
